Enovis (ENOV) Stock Overview
A medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ENOV from our risk checks.
ENOV Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.12 |
| 52 Week High | US$36.82 |
| 52 Week Low | US$21.00 |
| Beta | 1.52 |
| 1 Month Change | 4.06% |
| 3 Month Change | 19.98% |
| 1 Year Change | -26.90% |
| 3 Year Change | -52.58% |
| 5 Year Change | -80.11% |
| Change since IPO | -58.54% |
Recent News & Updates
Recent updates
Narrative Update • Apr 24
ENOV: Future Returns Will Likely Be Driven By FY26 Free Cash Flow
Narrative Update The updated analyst price target for Enovis edges lower by about $0.36, with analysts pointing to slightly higher discount-rate assumptions and modestly adjusted P/E expectations following recent target cuts from BTIG and Evercore ISI, partially balanced by fresh positive coverage from William Blair and Wells Fargo. Analyst Commentary Recent research on Enovis presents a mixed picture, with some analysts taking a more cautious stance on valuation while others are comfortable assuming positive coverage and rating the shares favorably.Narrative Update • Apr 09
ENOV: Future Returns Will Likely Benefit From FY26 Free Cash Flow Conversion
Analysts have trimmed their average Enovis price target slightly, with the latest fair value estimate edging from about $45.18 to $45.09 as they factor in recent Q4 trends, expectations for improving free cash flow in FY26, and fresh coverage that still leans positive on the stock. Analyst Commentary Recent research updates give a mixed but generally constructive read on Enovis, with attention centered on Q4 execution, free cash flow potential in FY26, and how these factors line up with current valuation targets.Narrative Update • Mar 26
ENOV: Future Returns Will Likely Benefit From FY26 Cash Flow Execution
Analysts have nudged their price expectations for Enovis higher, citing the assumed Overweight initiation at Wells Fargo, as well as expectations for stronger margins and improving free cash flow conversion. These factors support a slightly richer implied future P/E of about 143x and a maintained fair value estimate of about $45.18 per share.Narrative Update • Mar 12
ENOV: Future Returns Will Likely Benefit From FY26 Free Cash Flow Conversion
Narrative Update on Enovis The updated analyst price target for Enovis shifts slightly from about $45.09 to $45.18. Analysts point to expectations for improved free cash flow conversion, stronger profit margins in higher margin reconstruction, and a lower assumed discount rate as key supports for this modest change.Narrative Update • Feb 26
ENOV: Future Returns Will Likely Benefit From FY26 Free Cash Flow Conversion
Analysts have kept their price target for Enovis broadly unchanged near $40, citing expected improvements in free cash flow conversion into FY26 and solid Q4 EPS performance as key supports for their valuation. Analyst Commentary Bullish Takeaways Bullish analysts point to the implied 11% Q4 EPS beat as a sign that higher margin reconstructive products performed well, which they see as supportive for earnings quality at the current valuation.Seeking Alpha • Feb 12
Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth
Summary Enovis continues to struggle in the market, as institutional investors just aren't interested in mid-single-digit growth from a mid-cap name. Management has guided for up to low-double-digit Recon growth in 2026, but overall growth, margin leverage, and meaningful free cash flow generation remain key hurdles for rerating. Bringing successful products over from Europe could drive more growth in hips and shoulders, but it will take time and clinical trials to get them to the market. Valuation appears attractive on DCF and multiples; I maintain my "Buy" rating. Read the full article on Seeking AlphaNarrative Update • Feb 11
ENOV: Future Returns Will Likely Benefit From Strengthening Free Cash Flow Signals
Analysts have trimmed their fair value estimate for Enovis slightly from about $45.45 to $45.09. This reflects modest tweaks to assumptions on profit margin, discount rate and long term P/E, even as they highlight expectations for stronger free cash flow conversion over time.Narrative Update • Jan 27
ENOV: Future Returns Will Likely Benefit From Improving Free Cash Flow Conversion
Analysts have modestly adjusted their price assumptions for Enovis, citing the updated risk profile in their models and highlighting expectations for stronger free cash flow conversion, supported by recent commentary that cash flow is set to improve by FY26. Analyst Commentary Recent commentary has focused on how Enovis is balancing softer revenue expectations for Q4 with stronger earnings and a clearer free cash flow story into FY26.Narrative Update • Jan 11
ENOV: Future Returns Will Likely Benefit From Higher Assumed P/E Multiple
Analysts have trimmed their fair value estimate for Enovis from US$47.00 to about US$45.45, citing updated assumptions for discount rate, revenue growth, profit margin, and a much higher future P/E multiple. What's in the News Enovis updated its full year 2025 earnings guidance, with revenue now expected in a range of US$2.24b to US$2.27b, compared with the prior range of US$2.245b to US$2.275b (company guidance).Narrative Update • Dec 18
ENOV: Future Returns Will Likely Benefit From Completed Share Repurchases
Analysts have trimmed their price target on Enovis from 49.67 dollars to 47.00 dollars, as they now expect slower revenue growth, significantly lower profit margins, and a higher required return, partially offset by a richer future price to earnings multiple. What's in the News Enovis has fully completed its $200 million share repurchase program announced in February 2018, having bought back a total of 6,449,425 shares, representing 15.84% of its outstanding stock, with no additional shares repurchased between July 5 and October 3, 2025 (Key Developments).Analysis Article • Nov 09
Enovis Corporation (NYSE:ENOV) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
It's been a sad week for Enovis Corporation ( NYSE:ENOV ), who've watched their investment drop 10% to US$28.06 in the...Narrative Update • Sep 24
Next Generation Orthopedic Technology Will Transform Global Care
The modest decline in Enovis's future P/E and discount rate suggests slightly more conservative growth expectations and a lower required return, resulting in a decreased consensus price target from $52.20 to $49.67. What's in the News Enovis raised its full-year 2025 earnings guidance, now expecting revenue between $2.245 billion and $2.275 billion, above prior forecasts (Key Developments).Narrative Update • Aug 09
Next Generation Orthopedic Technology Will Transform Global Care
Enovis' price target has been revised lower, likely reflecting a modest decline in net profit margin despite slightly higher revenue growth expectations, resulting in a new consensus fair value of $53.40. What's in the News Enovis Corporation raised full-year 2025 revenue guidance to $2.245 billion–$2.275 billion, up from prior expectations of $2.220 billion–$2.250 billion.Analysis Article • Jul 21
Enovis Corporation's (NYSE:ENOV) Shares Lagging The Industry But So Is The Business
Enovis Corporation's ( NYSE:ENOV ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...New Narrative • May 14
New Product Pipeline Will Unlock International Orthopedic Markets
Successful product innovation and past acquisitions position Enovis for international market expansion and consistent revenue and earnings growth.Analysis Article • May 09
Is Enovis (NYSE:ENOV) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 01
Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1x Enovis Corporation ( NYSE:ENOV ) is definitely a stock...Analysis Article • Jan 20
Enovis (NYSE:ENOV) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Dec 13
Enovis Corporation's (NYSE:ENOV) Shares Not Telling The Full Story
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Enovis Corporation ( NYSE:ENOV ) is definitely a...Analysis Article • Sep 24
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 20
It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Enovis Corporation ( NYSE:ENOV ) is a stock worth...Seeking Alpha • Jul 15
Enovis Languishing Despite Respectable Performance
Summary Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment. Enovis should be trading around mid-$60s if mid-single-digit long-term growth and low-20%s EBITDA margins are valid targets. Read the full article on Seeking AlphaAnalysis Article • Jun 07
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • May 05
Enovis: Solid Growth, But Unstable Financial Footing
Summary Enovis, the medtech leftover of Colfax, has seen solid growth, but reports highly adjusted earnings and recently has taken on quite some leverage. The company competes in a wide range of activities in the orthopedic market, facing competition from large competitors such as Smith & Nephew and Stryker. Shares of Enovis have been stuck in a range and have underperformed the wider market, and while sales multiples look cheap, the financials are too adjusted to convince me. Read the full article on Seeking AlphaAnalysis Article • Apr 22
Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Enovis Corporation's ( NYSE:ENOV ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a buy right now...Analysis Article • Feb 12
Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enovis fair value estimate is US$72.49 Current share price of...Analysis Article • Jan 14
Is Enovis (NYSE:ENOV) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Dec 18
Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Enovis Corporation's ( NYSE:ENOV ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a buy right now...Shareholder Returns
| ENOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.1% | -2.5% | 1.1% |
| 1Y | -26.9% | -22.9% | 26.7% |
Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned -22.5% over the past year.
Return vs Market: ENOV underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| ENOV volatility | |
|---|---|
| ENOV Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENOV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 7,802 | Damien McDonald | www.enovis.com |
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
Enovis Corporation Fundamentals Summary
| ENOV fundamental statistics | |
|---|---|
| Market cap | US$1.48b |
| Earnings (TTM) | -US$1.14b |
| Revenue (TTM) | US$2.28b |
0.7x
P/S Ratio-1.3x
P/E RatioIs ENOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENOV income statement (TTM) | |
|---|---|
| Revenue | US$2.28b |
| Cost of Revenue | US$888.53m |
| Gross Profit | US$1.39b |
| Other Expenses | US$2.53b |
| Earnings | -US$1.14b |
Last Reported Earnings
Apr 03, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -19.72 |
| Gross Margin | 61.00% |
| Net Profit Margin | -49.83% |
| Debt/Equity Ratio | 89.6% |
How did ENOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 12:05 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/04/03 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enovis Corporation is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Robert Cornell | Barclays |
| Andrew Obin | BofA Global Research |